(Q38241710)

English

Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

immunosuppression

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Dixon B Kaufman

2

object named as

Dixon B Kaufman

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

author name string

Shamkant Mulgaonkar

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

publication date

4 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Clinical Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

1209-1224

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

FK 506 for liver, kidney, and pancreas transplantation

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation1,2

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

The natural history of chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Cyclosporin in therapeutic doses increases renal allograft vascular resistance.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Chronic calcineurin inhibitor nephrotoxicity-lest we forget

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Nox2 is a mediator of chronic CsA nephrotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Chronic progressive calcineurin nephrotoxicity: an overstated concept

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Thrombotic microangiopathy after renal transplantation in the United States

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Tacrolimus-induced neurotoxicity in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Tacrolimus: a further update of its use in the management of organ transplantation

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Comparison of cyclosporine and sirolimus effects on serum creatinine level over five years after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

mTOR inhibitor-associated proteinuria in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Long-term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

The prevalence of immunologic injury in renal allograft recipients with de novo proteinuria

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Increasing relevance of donor-specific antibodies in antibody-mediated rejection.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Identifying specific causes of kidney allograft loss.

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Diagnosis and prevention of chronic kidney allograft loss

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study

1 reference

https://api.crossref.org/works/10.1111%2FCTR.12453

21 January 2018

Identifiers

10.1111/CTR.12453

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38241710&oldid=1749007692"